Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye disease
Biotech
Atsena gene therapy hits safety goals, closes retinal splits
Gene therapy outfit Atsena Therapeutics has debuted data showing its eye disease candidate led to no serious treatment-related adverse events.
Darren Incorvaia
May 19, 2025 12:59pm
Beacon shines a light on positive early data from eye disease ph. 2
May 7, 2025 7:15am
Opthea lays off 65% of staff after back-to-back phase 3 flops
Apr 10, 2025 7:52am
Tenvie takes off with $200M, assets and exec from Denali
Jan 8, 2025 8:00am
mRNA therapy reduced post-surgery eye scarring in rabbits
Nov 27, 2024 2:00pm
AlloVir finds new identity via eye disease biotech merger
Nov 8, 2024 9:05am
